Pretibial myxedema is a skin condition caused by the buildup of a sugar-based molecule called hyaluronic acid in the deeper layers of skin, most commonly on the shins. It occurs almost exclusively in people with Graves’ disease, an autoimmune thyroid disorder, and affects roughly 0.5% to 4.3% of those patients. Despite its name, the condition has nothing to do with being hypothyroid. It’s driven by the same misdirected immune attack that causes Graves’ disease itself.
Why It Happens
In Graves’ disease, the immune system produces antibodies that stimulate receptors on thyroid cells, causing the gland to overproduce hormones. Those same receptors also exist at low levels in connective tissue throughout the body. In the skin of the shins, certain immune cells and local factors can cause these receptors to become overexpressed, making the tissue especially vulnerable.
When the autoantibodies bind to these receptors on skin cells called fibroblasts, the fibroblasts ramp up production of hyaluronic acid. This molecule has an extraordinary ability to absorb water, expanding up to 1,000 times its original volume. As it accumulates in the skin, it pushes apart and fragments collagen fibers, creating the thickened, swollen patches that define the condition. About 80% to 100% of people with pretibial myxedema have elevated levels of these stimulating antibodies in their blood.
What It Looks Like
The condition takes several forms. It can appear as raised plaques, firm nodules, diffuse swelling across the lower leg, or a combination of these. In about half of all cases, the skin develops a distinctive “orange peel” texture with visible, enlarged pores. Some people also notice increased hair growth over the affected area, localized sweating, or itching. Occasionally there’s a prickling sensation.
In a study of 216 patients, every single case involved the lower legs. Feet and toes were affected in about 30% of cases, while involvement of the arms, hands, or upper body was extremely rare. The most severe form, called elephantiasis, produces massive, coarse swelling with thickened, cracked skin resembling tree bark. This form is uncommon but particularly difficult to treat.
Connection to Graves’ Eye Disease
Pretibial myxedema rarely appears in isolation. It’s strongly linked to thyroid eye disease (Graves’ ophthalmopathy), which involves swelling and inflammation behind the eyes. Among Graves’ patients who already have eye involvement, the prevalence of pretibial myxedema rises to about 15%. Both conditions share the same underlying mechanism: autoantibody-driven accumulation of hyaluronic acid, just in different tissues. If you develop pretibial myxedema, there’s a good chance you’re also dealing with some degree of eye disease.
How It’s Diagnosed
Diagnosis is usually clinical, based on the characteristic appearance of skin changes on the shins in someone with known Graves’ disease. Blood tests for thyroid-stimulating antibodies support the diagnosis, though thyroid hormone levels themselves can be high, low, or normal depending on how the underlying thyroid condition is being managed.
When the diagnosis is uncertain, a skin biopsy can confirm it. Under the microscope, the hallmark finding is large deposits of mucin (the hyaluronic acid material) spread throughout the deeper layer of skin, with collagen fibers that look frayed and widely separated. Star-shaped fibroblasts are often visible, though fibroblast numbers aren’t actually increased. Special stains that turn blue in the presence of hyaluronic acid help distinguish pretibial myxedema from conditions that can look similar, like the skin changes caused by chronic poor circulation in the legs.
Treatment Options
Treatment aims to reduce the overproduction of hyaluronic acid by fibroblasts. The standard first-line approach uses high-potency topical corticosteroid creams applied under an occlusive dressing (a wrap that seals the medication against the skin) every night for four to six weeks. The occlusion is important because it dramatically increases how much of the medication penetrates into the deeper skin layers where the problem sits.
For thicker or more stubborn lesions, corticosteroids can be injected directly into the affected skin. This delivers a concentrated dose right where it’s needed and has shown good results in cases that don’t respond well to topical treatment alone. Compression therapy, using stockings or wraps, can provide additional benefit, particularly when there’s significant swelling or early elephantiasis.
Severe or widespread disease that doesn’t respond to corticosteroids has been treated with a range of other approaches, including medications that suppress the immune system more broadly. Rituximab, a drug that targets the B cells responsible for producing the offending antibodies, has been used in resistant cases. More recently, teprotumumab, a medication originally developed for Graves’ eye disease, has shown promise. In a published case, a patient with treatment-resistant pretibial myxedema experienced significant softening and shrinkage of her skin plaques during a course of teprotumumab infusions given every three weeks. However, the lesions began growing again about five months after treatment ended, suggesting the effect may be temporary.
Long-Term Outlook
Pretibial myxedema is a chronic condition, and improvement tends to be gradual. In a long-term study that followed 178 patients for an average of nearly eight years, about 26% experienced complete remission, another 24% had meaningful partial improvement, and the remaining 50% saw little or no change. Milder cases generally fare better. A separate analysis found that after 25 years, 70% of people with milder disease who went without aggressive treatment experienced at least partial remission on their own, while 58% of those with severe disease who received local therapy reached partial or full remission over the same timeframe.
The elephantiasis form carries the least favorable prognosis. All five elephantiasis cases in the long-term study were in the treated group, and they were the least likely to achieve remission. For most people, pretibial myxedema is a cosmetic and comfort issue rather than a dangerous one, but the slow pace of improvement and the possibility of persistence mean that managing expectations is an important part of living with it.